tbuckley/cabot-search huggingface dataset:
Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence
Authors: Vivian W. Sung, Diane Borello-France, Diane K. Newman, Holly E. Richter, Emily S. Lukacz, Pamela Moalli, Alison C. Weidner, Ariana L. Smith, Gena Dunivan, Beri Ridgeway, John N. Nguyen, Donna Mazloomdoost, Benjamin Carper, Marie G. Gantz
Journal: JAMA (2019)

<h3>Importance</h3> Mixed urinary incontinence, including both stress and urgency incontinence, has adverse effects on a woman's quality of life. Studies evaluating treatments to simultaneously improve both components are lacking. <h3>Objective</h3> To determine whether combining behavioral and pelvic floor muscle therapy with midurethral sling is more effective than sling alone for improving mixed urinary incontinence symptoms. <h3>Design, Setting, and Participants</h3> Randomized clinical trial involving women 21 years or older with moderate or severe stress and urgency urinary incontinence symptoms for at least 3 months, and at least 1 stress and 1 urgency incontinence episode on a 3-day bladder diary. The trial was conducted across 9 sites in the United States, enrollment between October 2013 and April 2016; final follow-up October 2017. <h3>Interventions</h3> Behavioral and pelvic floor muscle therapy (included 1 preoperative and 5 postoperative sessions through 6 months) combined with midurethral sling (n = 209) vs sling alone (n = 207). <h3>Main Outcomes and Measures</h3> The primary outcome was change between baseline and 12 months in mixed incontinence symptoms measured by the Urogenital Distress Inventory (UDI) long form; range, 0 to 300 points; minimal clinically important difference, 35 points, with higher scores indicating worse symptoms. <h3>Results</h3> Among 480 women randomized (mean [SD] age, 54.0 years [10.7]), 464 were eligible and 416 (86.7%) had postbaseline outcome data and were included in primary analyses. The UDI score in the combined group significantly decreased from 178.0 points at baseline to 30.7 points at 12 months, adjusted mean change −128.1 points (95% CI, −146.5 to −109.8). The UDI score in the sling-only group significantly decreased from 176.8 to 34.5 points, adjusted mean change −114.7 points (95% CI, −133.3 to −96.2). The model-estimated between-group difference (−13.4 points; 95% CI, −25.9 to −1.0;<i>P</i> = .04) did not meet the minimal clinically important difference threshold. Related and unrelated serious adverse events occurred in 10.2% of the participants (8.7% combined and 11.8% sling only). <h3>Conclusions and Relevance</h3> Among women with mixed urinary incontinence, behavioral and pelvic floor muscle therapy combined with midurethral sling surgery compared with surgery alone resulted in a small statistically significant difference in urinary incontinence symptoms at 12 months that did not meet the prespecified threshold for clinical importance. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01959347
Association of Pediatric Obesity Treatment, Including a Dietary Component, With Change in Depression and Anxiety
Authors: Hiba Jebeile, Megan L. Gow, Louise A. Baur, Sarah P. Garnett, Susan J. Paxton, Natalie B. Lister
Journal: JAMA Pediatrics (2019)

Children and adolescents with obesity are at higher risk of developing depression and anxiety, and adolescent dieting is a risk factor for the development of depression. Therefore, determining the psychological effect of obesity treatment interventions is important to consider.To investigate the association between obesity treatment interventions, with a dietary component, and the change in symptoms of depression and anxiety in children and adolescents with overweight/obesity.Searches of MEDLINE, Embase, Cochrane Library, and PsychINFO were conducted from inception to August 2018. Hand searching of references was conducted to identify missing studies.Obesity treatment interventions, with a dietary component, conducted in children and adolescents (age <18 years) with overweight/obesity, and validated assessment of depression and/or anxiety were included.Data were independently extracted by 1 reviewer and checked for accuracy. Meta-analysis, using a random-effects model, was used to combine outcome data and moderator analysis conducted to identify intervention characteristics that may influence change in depression and anxiety. The meta-analyses were finalized in May 2019.Change in symptoms of depression and anxiety postintervention and at the latest follow-up.Of 3078 articles screened, 44 studies met inclusion criteria with a combined sample of 3702 participants (age range, 5.6 to 16.6 years) and intervention duration of 2 weeks to 15 months. Studies reported either no change or a statistically significant reduction in symptoms of depression or anxiety. Meta-analyses of 36 studies found a reduction in depressive symptoms postintervention (standardized mean difference [SE], -0.31 [0.04]; P < .001), maintained at follow-up in 11 studies at 6 to 16 months from baseline (standardized mean difference [SE], -0.25 [0.07]; P < .001). Anxiety was reduced postintervention (10 studies; standardized mean difference [SE], -0.38 [0.10]; P < .001) and at follow-up (4 studies; standardized mean difference [SE], -0.32 [0.15]; P = .03). Longer intervention duration was associated with a greater reduction in anxiety (R2 = 0.82; P < .001). Higher body mass index z score at baseline was associated with a greater reduction in depression (R2 = 0.19; P = .03).Structured, professionally run pediatric obesity treatment is not associated with an increased risk of depression or anxiety and may result in a mild reduction in symptoms. Treatment of weight concerns should be considered within the treatment plan for young people with depression and obesity.
Abstract 13005: Pilot Study of Edetate Disodium-Based Chelation in Diabetics With Critical Limb Ischemia
Authors: Ivan A Arenas, Francisco Ujueta, Denisse Diaz, Ana Navas-Acien, Robert Beasley, Timothy Yates, Brandon Olivieri, Gervasio A Lamas
Journal: Circulation (2018)

Critical limb ischemia (CLI) carries over a 60% risk of major events (death, major amputation, or myocardial infarction) at 1-year. The Trial to Assess Chelation Therapy (TACT), demonstrated a majo...
Syncope After Percutaneous Coronary Intervention
Authors: Takahiro Tsushima, Jayakumar Sahadevan, Anselma Intini
Journal: JAMA Cardiology (2019)

A man in his late 50s with a history of remote coronary artery bypass grafting presents with unstable angina and experiences worsening exertional dyspnea and multiple episodes of syncope after undergoing percutaneous coronary intervention with a drug-eluting stent. What would you do next?
Abstract 12352: Beta-Blockers for the Prevention of Anthracycline-Induced Cardiomyopathy: Systematic Review and Meta-Analysis
Authors: Leonardo M Knijnik, Manuel Rivera, Amanda D Fernandes, Rhanderson M Cardoso, Mauricio Cohen
Journal: Circulation (2018)

Introduction: Anthracycline-induced cardiomyopathy persists as an important complication in anthracycline-treated patients, with more than 30% of patients developing cardiomyopathy after very high ...
Abstract 14543: The Efficacy of MICS-Mitral Valve Repair: Comparison With Median Sternotomy
Authors: Yasushi Yoshikawa, Koichi Toda, Shigeru Miyagawa, Hiroki Hata, Daisuke Yoshioka, Satoshi kainuma, Ryohei Matsuura, Shohei Yoshida, Yoshiki Sawa
Journal: Circulation (2018)

Introduction: Minimally invasive approaches (MICS) to mitral valve surgery have prevailed recently, but have potential pitfalls because of its limited field. The MICS mustn’t compromise the clinica...
Checklist for Initial Triage After an Anthrax Mass Exposure Event
Authors: Alan R. Ertle
Journal: Annals of Internal Medicine (2019)

Letters17 September 2019Checklist for Initial Triage After an Anthrax Mass Exposure EventAlan R. Ertle, MD, MPH, MBAAlan R. Ertle, MD, MPH, MBAEmeritus Enterprises, Bend, Oregon (A.R.E.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0378 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I was confused by Hupert and colleagues' article (1) outlining their development of a checklist to triage patients after an anthrax mass exposure event. The event that they describe—a wide-area aerosol release of Bacillus anthracis spores (Ba-WAAR)—is purposeful and enacted by a terrorist. This scenario differs greatly from the incidences of letters containing anthrax spores that started in September 2001. Inhalation anthrax would be the primary concern in a Ba-WAAR, not the cutaneous and gastrointestinal form.A Ba-WAAR poses 2 possible scenarios: The potential exposure due to the event would be known at the outset, or the ...Reference1. Hupert N, Person M, Hanfling D, et al. Development and performance of a checklist for initial triage after an anthrax mass exposure event. Ann Intern Med. 2019. [PMID: 30884525] doi:10.7326/M18-1817 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Emeritus Enterprises, Bend, Oregon (A.R.E.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0378. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDevelopment and Performance of a Checklist for Initial Triage After an Anthrax Mass Exposure Event Nathaniel Hupert , Marissa Person , Dan Hanfling , Rita M. Traxler , William A. Bower , and Katherine Hendricks Checklist for Initial Triage After an Anthrax Mass Exposure Event Bing-Kun Zheng Checklist for Initial Triage After an Anthrax Mass Exposure Event Nathaniel Hupert , Marissa Person , Dan Hanfling , Rita Traxler , William A. Bower , and Katherine Hendricks Metrics 17 September 2019Volume 171, Issue 6Page: 448-449KeywordsAlgorithmsAnthraxBacillus anthracisConflicts of interestDisclosureInhalationPostexposure prophylaxisTriage ePublished: 17 September 2019 Issue Published: 17 September 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Orbital Metastasis in Breast Cancer
Authors: Alejandro Salinas-Botrán, Maria J Guarín-Corredor
Journal: New England Journal of Medicine (2019)

A 60-year-old woman with a history of breast cancer presented with blurred vision. Examination revealed proptosis and an inability to look up with the left eye (shown in a video). MRI showed a mass involving the inferior rectus muscle, a finding consistent with a metastatic lesion.
The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies
Authors: Peter Jandus, Kayluz Frias Boligan, David F. Smith, Elisabeth de Graauw, Bodo Grimbacher, Camilla Jandus, Mai M. Abdelhafez, Alain Despont, Nicolai Bovin, Dagmar Simon, Robert Rieben, Hans-Uwe Simon, Richard D. Cummings, Stephan von Gunten
Journal: Blood (2019)
Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer
Authors: Mary-Ellen Taplin, Emmanuel S. Antonarakis, Karen J. Ferrante, Kerry Horgan, Brent Blumenstein, Fred Saad, Jun Luo, Johann S. de Bono
Journal: European Urology (2019)
Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent<i>CCNE1</i>and<i>IGF2</i>enhancer hijacking in primary gastric adenocarcinoma
Authors: Wen Fong Ooi, Amrita M Nargund, Kevin Junliang Lim, Shenli Zhang, Manjie Xing, Amit Mandoli, Jing Quan Lim, Shamaine Wei Ting Ho, Yu Guo, Xiaosai Yao, Suling Joyce Lin, Tannistha Nandi, Chang Xu, Xuewen Ong, Minghui Lee, Angie Lay-Keng Tan, Yue Ning Lam, Jing Xian Teo, Atsushi Kaneda, Kevin P White, Weng Khong Lim, Steven G Rozen, Bin Tean Teh, Shang Li, Anders J Skanderup, Patrick Tan
Journal: Gut (2019)

Genomic structural variations (SVs) causing rewiring of cis-regulatory elements remain largely unexplored in gastric cancer (GC). To identify SVs affecting enhancer elements in GC (enhancer-based SVs), we integrated epigenomic enhancer profiles revealed by paired-end H3K27ac ChIP-sequencing from primary GCs with tumour whole-genome sequencing (WGS) data (PeNChIP-seq/WGS).We applied PeNChIP-seq to 11 primary GCs and matched normal tissues combined with WGS profiles of >200 GCs. Epigenome profiles were analysed alongside matched RNA-seq data to identify tumour-associated enhancer-based SVs with altered cancer transcription. Functional validation of candidate enhancer-based SVs was performed using CRISPR/Cas9 genome editing, chromosome conformation capture assays (4C-seq, Capture-C) and Hi-C analysis of primary GCs.PeNChIP-seq/WGS revealed ~150 enhancer-based SVs in GC. The majority (63%) of SVs linked to target gene deregulation were associated with increased tumour expression. Enhancer-based SVs targeting CCNE1, a key driver of therapy resistance, occurred in 8% of patients frequently juxtaposing diverse distal enhancers to CCNE1 proximal regions. CCNE1-rearranged GCs were associated with high CCNE1 expression, disrupted CCNE1 topologically associating domain (TAD) boundaries, and novel TAD interactions in CCNE1-rearranged primary tumours. We also observed IGF2 enhancer-based SVs, previously noted in colorectal cancer, highlighting a common non-coding genetic driver alteration in gastric and colorectal malignancies.Integrated paired-end NanoChIP-seq and WGS of gastric tumours reveals tumour-associated regulatory SV in regions associated with both simple and complex genomic rearrangements. Genomic rearrangements may thus exploit enhancer-hijacking as a common mechanism to drive oncogene expression in GC.
A social empowerment intervention to prevent intimate partner violence against women in a microfinance scheme in Tanzania: findings from the MAISHA cluster randomised controlled trial
Authors: Saidi Kapiga, Sheila Harvey, Gerry Mshana, Christian Holm Hansen, Grace J Mtolela, Flora Madaha, Ramadhan Hashim, Imma Kapinga, Neema Mosha, Tanya Abramsky, Shelley Lees, Charlotte Watts
Journal: The Lancet Global Health (2019)

Globally, about 30% of women have experienced physical or sexual violence, or both, from an intimate partner during their lifetime. Associations between poverty and women's increased risk of intimate partner violence have been observed. We therefore aimed to assess the effect of a violence prevention intervention delivered to women participating in a group-based microfinance scheme in Tanzania.
Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Authors: Leylah M. Drusbosky, Kimberly E. Hawkins, Madeleine Turcotte, Hemant S. Murthy, Helen L. Leather, Nosha Farhadfar, Maxim Norkin, John R. Wingard, John W. Hiemenz, Paul Castillo, Randy A. Brown, William Slayton, Biljana N. Horn, Sumanth Vasista, Kabya Basu, Shahabuddin Usmani, Kunal Ghosh Roy, Deepak Anil Lala, Saumya Radhakrishnan, Rajeev Kumar, Swaminathan Rajagopalan, Taher Abbasi, Shireen Vali, Christopher R. Cogle
Journal: Blood (2017)
A Single Center Retrospective Evaluation of Daratumumab Infusion Related Reactions with Split-First Dose Day 1 and Day 2 Infusion
Authors: Ali McBride, Muhammad Usman, Muhammad Jahanzeb Khalil, Muhammad Junaid Tariq, Muhammad Asad Fraz, Awais Ijaz, Malik Qistas Ahmad, Ali Younas Khan, Sharoon Samuel, Insija Ilyas Selene, James Camamo, Cara Chang, Jemin Aby Jose, Faiz Anwer
Journal: Blood (2018)
2019 ACC Health Policy Statement on Cardiologist Compensation and Opportunity Equity
Authors: Pamela S. Douglas, Cathleen Biga, Kristin M. Burns, Richard A. Chazal, Michael S. Cuffe, James M. Daniel, Catherine Garzio, Robert A. Harrington, Hena N. Patel, Mary Norine Walsh, Michael J. Wolk
Journal: Journal of the American College of Cardiology (2019)
The T2Bacteria Panel had 90% sensitivity for detecting targeted organisms, 43% for any bloodstream infection organism
Authors: Dennis G. Maki
Journal: Annals of Internal Medicine (2019)

Source Citation Nguyen MH, Clancy CJ, Pasculle AW, et al. Performance of the T2Bacteria Panel for diagnosing bloodstream infections: a diagnostic accuracy study. Ann Intern Med. 2019;170:845-52. 31083728
Acute Care for Patients Who Are Incarcerated
Authors: Lawrence A. Haber, Hans P. Erickson, Sumant R. Ranji, Gabriel M. Ortiz, Lisa A. Pratt
Journal: JAMA Internal Medicine (2019)

The United States has the world's highest rate of incarceration. Clinicians practicing outside of correctional facilities receive little dedicated training in the care of patients who are incarcerated, are unaware of guidelines for the treatment of patients in custody, and practice in health care systems with varying policies toward these patients. This review considers legal precedents for care of individuals who are incarcerated, frequently encountered terminology, characteristics of hospitalized incarcerated patients, considerations for clinical management, and challenges during transitions of care.The Eighth Amendment of the US Constitution mandates basic health care for incarcerated individuals within or outside of dedicated correctional facilities. Incarcerated patients in the acute hospital setting are predominantly young men who have received trauma-related admitting diagnoses. Hospital practices pertaining to privacy, physical restraint, discharge counseling, and surrogate decision-making are affected by a patient's incarcerated status under state or federal law, institutional policy, and individual health care professional practice. Transitions of care necessitate consideration of the disparate medical resources of correctional facilities as well as awareness of transitions unique to incarcerated individuals, such as compassionate release.Patients who are incarcerated have a protected right to health care but may experience exceptions to physical comfort, health privacy, and informed decision-making in the acute care setting. Research on the management of issues associated with hospitalized incarcerated patients is limited and primarily focuses on the care of pregnant women, a small portion of all hospitalized incarcerated individuals. Clinicians and health care facilities should work toward creating evidence-based and legally supported guidelines for the care of incarcerated individuals in the acute care setting that balance the rights of the patient, responsibilities of the clinician, and safety mandates of the institution and law enforcement.
mTORC1 feedback to AKT modulates lysosomal biogenesis through MiT/TFE regulation
Authors: Kaushal Asrani, Sanjana Murali, Brandon Lam, Chan-Hyun Na, Pornima Phatak, Akshay Sood, Harsimar Kaur, Zoya Khan, Michaël Noë, Ravi K Anchoori, C Conover Talbot, Barbara Smith, Michael Skaro, Tamara L Lotan
Journal: Journal of Clinical Investigation (2019)

The microphthalmia family of transcription factors (MiT/TFEs) controls lysosomal biogenesis and is negatively regulated by the nutrient sensor mTORC1. However, the mechanisms by which cells with constitutive mTORC1 signaling maintain lysosomal catabolism remain to be elucidated. Using the murine epidermis as a model system, we found that epidermal Tsc1 deletion resulted in a phenotype characterized by wavy hair and curly whiskers, and was associated with increased EGFR and HER2 degradation. Unexpectedly, constitutive mTORC1 activation with Tsc1 loss increased lysosomal content via upregulated expression and activity of MiT/TFEs, whereas genetic deletion of Rheb or Rptor or prolonged pharmacologic mTORC1 inactivation had the reverse effect. This paradoxical increase in lysosomal biogenesis by mTORC1 was mediated by feedback inhibition of AKT, and a resulting suppression of AKT-induced MiT/TFE downregulation. Thus, inhibiting hyperactive AKT signaling in the context of mTORC1 loss-of-function fully restored MiT/TFE expression and activity. These data suggest that signaling feedback loops work to restrain or maintain cellular lysosomal content during chronically inhibited or constitutively active mTORC1 signaling, respectively, and reveal a mechanism by which mTORC1 regulates upstream receptor tyrosine kinase signaling.
Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival (“Potential Cure”) over the Past Four Decades: Analysis of SWOG Trial Data
Authors: Megan Othus, Guillermo Garcia-Manero, John Godwin, James K. Weick, Jeanne E. Anderson, Derek Stirewalt, Frederick R. Appelbaum, Harry P. Erba, Elihu H. Estey
Journal: Blood (2017)
Expanding the Scope of Multimodality Imaging in Durable Mechanical Circulatory Support
Authors: Zaid I. Almarzooq, Anubodh S. Varshney, Muthiah Vaduganathan, Manan Pareek, Garrick C. Stewart, Jerry D. Estep, Mandeep R. Mehra
Journal: JACC. Cardiovascular imaging (2019)
Nucleoside diphosphate kinase A/NM23-H1 binds to the c-myc promoter and regulates its transcription
Authors: Christina L. Chang
Journal: Cancer Research (2004)

976  Nucleoside diphosphate kinase isoforms A (NDPK-A) and B (NDPK-B) share 88% identical amino acid residues and are encoded by the nm23-H1 and nm23-H2 genes, respectively. NDPK-B has been shown to regulate c-myc transcription via the nuclease hypersensitive element (NHE) III1, it is likely that NDPK-A has a similar function because of its homology and interaction with NDPK-B. In this study, we have demonstrated that NDPK-A formed a complex with c-myc NHE III1, spanning from –142 to –115 relative to the P1 start site, in the electrophoretic mobility shift assay (EMSA). NDPK-A interacted specifically with double-stranded (ds) as well as single-stranded (ss) c-myc based on DNA competition and protein depletion experiments. NDPK-A bound to the pyrimidine- and purine-rich strand with similar affinity. Compared to NDPK-B, however, NDPK-A displayed a significant lower binding affinity toward c-myc DNA based on EMSA and UV-crosslinking. Similar to many human cancer cell lines, NB69 neuroblastoma cells expressed detectable NDPK-B, but not NDPK-A, according to Western blot analysis. Deletion of the NHE III1 (i.e., –293 to –104) from the c-myc promoter, spanning from –1676 to +374, de-repressed the CAT activity by approximately 6 folds. Stable transfectants established from NB69 cells overexpressed NDPK-A and the latter was localized to nuclei by immunohistochemistry. These transfectants only de-repressed the CAT activity by 3 folds when the NHE III1 was deleted from the c-myc promoter. Additional de-repression appeared to require c-myc promoter region upstream of the NHE III1. Our findings suggest that NDPK-A participates in the regulation of c-myc transcription by directly interacts with NHE III1 in the promoter. Alternatively, NDPK-A may be indirectly involved in c-myc gene regulation by affecting the DNA-binding ability of NDPK-B via the protein-protein interaction. NDPK-B appeared to repress c-myc transcription in human neuroblastoma cell, perhaps via tissue-specific proteins that regulate c-myc promoter.